Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Flutamide Clear all
Completed Early Phase 1 Interventional Results available

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

NCT03507608
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Placebo
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 2 Interventional

Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00003124
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, leuprolide acetate, radiation therapy
Drug · Radiation
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

NCT00001521
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia (CAH)
Interventions
Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 4, 2026, 1:52 AM EDT
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NCT04513717
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
594
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 4, 2026, 1:52 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome

NCT00930228
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Flutamide, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

NCT02090114
View directory record Official record
Conditions
Prostate Cancer
Interventions
Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

NCT01889199
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
Flutamide, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 2 Interventional

Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate

NCT00006214
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
22
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 4, 2026, 1:52 AM EDT
Active, not recruiting Phase 1 Interventional

Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

NCT05983198
View directory record Official record
Conditions
Prostate Cancer
Interventions
225Ac-PSMA-R2, 68Ga-PSMA-R2, 68Ga-PSMA-11
Drug · Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer

NCT00223665
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Leuprolide Acetate
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

NCT00170157
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Bicalutamide, Flutamide, Goserelin Acetate, Ipilimumab, Leuprolide Acetate, Pharmacological Study
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00028769
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00528866
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, docetaxel, flutamide, LHRH agonist, 3-dimensional conformal radiation therapy, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
69
States / cities
Phoenix, Arizona • Auburn, California • Cameron Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 2 Interventional

Hormone Therapy in Treating Patients With Prostate Cancer

NCT00003323
View directory record Official record
Conditions
Prostate Cancer, Sexual Dysfunction and Infertility
Interventions
finasteride, flutamide, quality-of-life assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00005044
View directory record Official record
Conditions
Prostate Cancer
Interventions
Casodex, Eulexin, LHRH agonist, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2022
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

NCT00309985
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
androgen-deprivation therapy, docetaxel
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
343
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 243 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 4, 2026, 1:52 AM EDT
Terminated Not applicable Interventional Results available

Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome

NCT00729560
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Flutamide, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Sep 4, 2026, 1:52 AM EDT
Active, not recruiting Not applicable Interventional Results available

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

NCT05628363
View directory record Official record
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy
Device · Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 4, 2026, 1:52 AM EDT
Recruiting Phase 3 Interventional

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

NCT03678025
View directory record Official record
Conditions
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
334
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

NCT00283803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 3 Interventional

Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer

NCT00116220
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide (Eulexin) and Lupron or Zoladex, External Beam Radiotherapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
41 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 4, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00002597
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, Zoladex, Lupron, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2018
U.S. locations
222
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 4, 2026, 1:52 AM EDT
Not listed No phase listed Observational

Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

NCT00850941
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
3
States / cities
Albuquerque, New Mexico • Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 4, 2026, 1:52 AM EDT